ATE444960T1 - Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer - Google Patents

Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer

Info

Publication number
ATE444960T1
ATE444960T1 AT00984681T AT00984681T ATE444960T1 AT E444960 T1 ATE444960 T1 AT E444960T1 AT 00984681 T AT00984681 T AT 00984681T AT 00984681 T AT00984681 T AT 00984681T AT E444960 T1 ATE444960 T1 AT E444960T1
Authority
AT
Austria
Prior art keywords
stilbenoxides
polyhydroxystilbenes
protein kinase
kinase inhibitors
antipsoriasis agents
Prior art date
Application number
AT00984681T
Other languages
English (en)
Inventor
Genhui Chen
John Webster
Jianxiong Li
Kaiji Hu
Jiang Zhu
Original Assignee
Welichem Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Welichem Biotech Inc filed Critical Welichem Biotech Inc
Application granted granted Critical
Publication of ATE444960T1 publication Critical patent/ATE444960T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/16—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by esterified hydroxyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/14—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by free hydroxyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00984681T 1999-12-06 2000-12-06 Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer ATE444960T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16875899P 1999-12-06 1999-12-06
US17330099P 1999-12-28 1999-12-28
PCT/CA2000/001433 WO2001042231A2 (en) 1999-12-06 2000-12-06 Polyhydroxystilbenes and stilbene oxides as antisoriatic agents and protein kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE444960T1 true ATE444960T1 (de) 2009-10-15

Family

ID=26864425

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00984681T ATE444960T1 (de) 1999-12-06 2000-12-06 Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer

Country Status (10)

Country Link
US (1) US20030171429A1 (de)
EP (1) EP1248774B1 (de)
JP (1) JP4880847B2 (de)
KR (1) KR100805907B1 (de)
CN (1) CN1319959C (de)
AT (1) ATE444960T1 (de)
CA (1) CA2393297C (de)
DE (1) DE60043120D1 (de)
ES (1) ES2334635T3 (de)
WO (1) WO2001042231A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7321050B2 (en) 1999-12-06 2008-01-22 Welichem Biotech Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
US6552085B2 (en) 2000-08-16 2003-04-22 Insmed Incorporated Compositions containing hypoglycemically active stilbenoids
US6410596B1 (en) * 2000-08-16 2002-06-25 Insmed Incorporated Compositions containing hypoglycemically active stillbenoids
AU2002226225B2 (en) 2001-01-18 2008-03-20 Dermavant Sciences GmbH Novel 1,2-diphenylethene derivatives for treatment of immune diseases
JP4425628B2 (ja) * 2001-07-23 2010-03-03 ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド 細胞保護化合物、薬学的処方物および美容用処方物、ならびに方法
CN1398838A (zh) 2001-07-26 2003-02-26 中国人民解放军军事医学科学院放射医学研究所 二苯乙烯类化合物制备以及它们在治疗和预防糖尿病中的应用
FR2830860A1 (fr) * 2001-10-12 2003-04-18 Univ Pasteur Procede de synthese du (z)-3, 5, 4'-trimethoxystilbene, compose obtenu et utilisations dudit compose, notamment comme medicament, en particulier comme anticancereux
CN100586428C (zh) * 2001-11-02 2010-02-03 加州大学校务委员会 用于预防和治疗炎性疾病,自体免疫性疾病,和移植排斥的组成物及其制药用途
CA2501719C (en) * 2002-08-06 2013-02-05 Toray Industries, Inc. Remedy or preventive for kidney disease and method of diagnosing kidney disease
US20050080024A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
US20050080021A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders
AU2003272548A1 (en) * 2002-09-16 2004-04-30 Plexxikon, Inc. Crystal structure of pim-1 kinase
AU2003271470B2 (en) * 2002-10-01 2010-03-18 Welichem Biotech Inc. Novel bioactive diphenyl ethene compounds and their therapeutic applications
GB2411353A (en) * 2004-02-25 2005-08-31 Univ Hertfordshire Resveratrol Analogues
WO2006045010A2 (en) * 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
US8410109B2 (en) * 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
US20090182003A1 (en) * 2006-01-13 2009-07-16 President And Fellows Of Harvard College Methods and Compositions for Treatment Cell Proliferative Disorders
US8980954B2 (en) * 2006-04-25 2015-03-17 Stc.Unm Substituted cis- and trans-stilbenes as therapeutic agents
PT2118074E (pt) * 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
US20100130597A1 (en) * 2007-07-06 2010-05-27 The United State Of America, As Represented By The Secretary Of The Dept Of Health And Human Service Dna-pkcs modulates energy regulation and brain function
FI125590B (en) 2008-04-10 2015-12-15 Neste Oyj A process for the preparation of a composition for the preparation of pinosylvine and its compounds, a composition for the preparation of stilbene compounds, a process for the recovery of stilbene compounds, and fatty acid and resin acid esters of pinosylvine and its monomethyl ether
SI2346837T1 (sl) 2008-06-26 2015-05-29 Resverlogix Corporation Postopki pripravljanja kinazolinonskih derivatov
WO2010046926A2 (en) * 2008-10-17 2010-04-29 Aptuit Laurus Pvt Ltd Novel stilbene analogs
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
US9050284B2 (en) * 2009-02-09 2015-06-09 Sami Labs Limited Orally bioavailable stilbenoids—compositions and therapeutic applications thereof
US20100204340A1 (en) * 2009-02-09 2010-08-12 Muhammed Majeed Orally bioavailable stilbenoids- compositions and therapeutic applications thereof
KR101913109B1 (ko) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
CN101531571B (zh) * 2009-04-17 2013-03-20 河北科技大学 六次甲基四胺氧化合成二苯乙烯类化合物的方法
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
CN101543477B (zh) * 2009-05-06 2011-01-19 河北科技大学 壳聚糖包覆3,5-二羟基-4-异丙基二苯乙烯的缓释微球及其制备方法
CN101564537B (zh) * 2009-06-08 2011-05-25 河北科技大学 3，5-二羟基-4-异丙基二苯乙烯-溴乙酸乙酯-聚乙二醇复合物及其合成方法
CN101564538B (zh) * 2009-06-08 2011-12-07 河北科技大学 3，5-二羟基-4-异丙基二苯乙烯-丁二酸酐-聚乙二醇复合物及其合成方法
CA2851996C (en) 2011-11-01 2020-01-07 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
CN102579322B (zh) * 2012-03-29 2013-10-23 河北科技大学 一种外用水凝胶剂及其制备方法与它的用途
CN102657602B (zh) * 2012-05-22 2013-08-07 河北科技大学 3,5-二羟基-4-异丙基二苯乙烯壳聚糖凝胶剂及其制备方法
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
US10376475B2 (en) 2014-12-12 2019-08-13 Dermavant Sciences GmbH Method of use
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
PT3297605T (pt) 2015-05-21 2022-05-30 Dermavant Sciences GmbH Composições farmacêuticas tópicas
CN106467502A (zh) * 2015-08-21 2017-03-01 南京理工大学 2,3-二芳基环氧乙烷化合物及其制备方法
US9725406B1 (en) * 2016-10-13 2017-08-08 Resolvex Pharmaceuticals Inc. Substituted hydroxystilbenes and their therapeutic applications
SG11202002576TA (en) * 2017-11-10 2020-04-29 Dermavant Sciences GmbH Process for preparing tapinarof
KR102233566B1 (ko) * 2018-05-04 2021-03-30 서울대학교산학협력단 스틸벤 유도체를 포함하는 만성 폐질환의 예방 또는 치료용 조성물
US11497718B2 (en) 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
EP4003299A4 (de) * 2019-07-24 2023-08-23 Sol-Gel Technologies Ltd. Behandlung von hauterkrankungen mit topischen tapinarof-egfr-inhibitorzusammensetzungen
WO2021236709A1 (en) 2020-05-19 2021-11-25 Teva Pharmaceuticals International Gmbh Solid state forms of tapinarof
CN113735693B (zh) * 2021-10-20 2023-07-14 河北维达康生物科技有限公司 一种白藜芦醇三甲醚的合成方法
CN116350609A (zh) * 2021-12-28 2023-06-30 上海泽德曼医药科技有限公司 用于抑制血管内皮生长的化合物及其用途
CN117003620B (zh) * 2022-05-07 2026-04-28 南京济群医药科技股份有限公司 作为AhR激动剂的二苯乙烯衍生物及其用途
CN115557963A (zh) * 2022-06-13 2023-01-03 大连大学 一类具有抗炎活性的聚酮类化合物及其制备方法和应用
WO2025021674A2 (en) 2023-07-21 2025-01-30 Interquim, S.A. Process for the preparation of tapinarof
WO2025031935A1 (en) 2023-08-04 2025-02-13 Sandoz Ag Crystalline forms of tapinarof
CN117447307A (zh) * 2023-11-01 2024-01-26 斯坦德药典标准物质研发(湖北)有限公司 一种Tapinarof的制备方法
IT202300023508A1 (it) 2023-11-08 2025-05-08 Procos Spa Processo per la preparazione della forma polimorfa iii di tapinarof
WO2025133100A1 (en) 2023-12-22 2025-06-26 Interquim, S.A. Process for the preparation of intermediates useful for the preparation of tapinarof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5111748A (en) * 1974-07-16 1976-01-30 Taisho Pharmaceutical Co Ltd Suchirubenjudotaino seizoho
JPS58159410A (ja) * 1982-03-18 1983-09-21 Mitsubishi Chem Ind Ltd 抗炎症剤
JPS6122046A (ja) * 1984-07-07 1986-01-30 Koichi Shiyudo スチルベン誘導体
DE3580134D1 (de) * 1984-07-07 1990-11-22 Shudo Koichi Prof Dr Chem Benzoesaeurederivate.
LU85558A1 (fr) * 1984-09-28 1986-04-03 Oreal Nouveaux derives naphtaleniques a action retinoique,leurs procedes de preparation et compositions medicamenteuse et cosmetique les contenant
US4788304A (en) * 1987-12-07 1988-11-29 American Home Products Corporation Phospholipase A2 inhibitors
US4933365A (en) * 1989-01-25 1990-06-12 American Home Products Corporation Phospholipase A2 inhibitors
GB9106177D0 (en) * 1991-03-22 1991-05-08 Aston Molecules Ltd Substituted diphenylethylenes and analogues or derivatives thereof
FR2676052B1 (fr) * 1991-05-02 1994-04-29 Cird Galderma Nouveaux composes polycycliques aromatiques et leur utilisation en medecine humaine ou veterinaire et en cosmetique.
GB9204945D0 (en) * 1992-03-06 1992-04-22 Erba Carlo Spa 3-aryl-glycidic ester derivatives and process for their preparation
US5430062A (en) * 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
JPH0753359A (ja) * 1993-06-11 1995-02-28 Kao Corp リポキシゲナーゼ阻害剤
US5556996A (en) * 1994-12-29 1996-09-17 Allergan Oxiranyls disubstituted with a phenyl group and a substituted chromanyl or tetrahydroquinolinyl group having retinoid like activity
JPH08337523A (ja) * 1995-06-14 1996-12-24 Taiho Yakuhin Kogyo Kk 血管新生阻害剤
US6008260A (en) * 1998-01-09 1999-12-28 Pharmascience Cancer chemopreventative composition and method
JP4642226B2 (ja) * 1998-02-06 2011-03-02 デ モントフォート ユニヴァーシティ ヒドロキシル化により活性化されたプロドラッグ
AU4084599A (en) * 1998-05-18 1999-12-06 Oklahoma Medical Research Foundation Resveratrol inhibition of myeloperoxidase
FR2785284B1 (fr) * 1998-11-02 2000-12-01 Galderma Res & Dev Analogues de la vitamine d

Also Published As

Publication number Publication date
KR100805907B1 (ko) 2008-02-21
AU780700B2 (en) 2005-04-14
EP1248774B1 (de) 2009-10-07
US20030171429A1 (en) 2003-09-11
KR20020070310A (ko) 2002-09-05
DE60043120D1 (de) 2009-11-19
CN1319959C (zh) 2007-06-06
ES2334635T3 (es) 2010-03-15
CA2393297A1 (en) 2001-06-14
HK1051691A1 (en) 2003-08-15
WO2001042231A3 (en) 2001-11-01
JP2003516400A (ja) 2003-05-13
CA2393297C (en) 2010-10-05
WO2001042231A2 (en) 2001-06-14
AU2133001A (en) 2001-06-18
EP1248774A2 (de) 2002-10-16
CN1407978A (zh) 2003-04-02
JP4880847B2 (ja) 2012-02-22

Similar Documents

Publication Publication Date Title
ATE444960T1 (de) Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
ATE249214T1 (de) Pentafluorobenzensulfonamide und analoge
PT1115701E (pt) Ureias de arilsulfonanilida
EP1689713A4 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
MY124122A (en) Heterocyclic derivatives
PT863891E (pt) (metilsulfonil)fenil-2-(5h)furanonas como inibidores de cox-2
EP1562897A4 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DE60120691D1 (de) Zusammensetzungen zur verwendung bei der behandlung der osteoporose und/oder der entzündlichen gelenkerkrankungen
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
ATE396973T1 (de) Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
PL343706A1 (en) Heterocyclic derivatives which inhibit factor xa
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
NZ330944A (en) Peptide derivatives
ES2189165T3 (es) Nuevos compuestos macrociclicos como inhibidores de metaloproteasa.
EE200100125A (et) TAN-1057 derivaadid
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
TR200200278T2 (tr) Kalsilitik bileşimler
ATE248845T1 (de) Arylsulfonanilid-phosphate
BRPI0415355A (pt) triarilimidazóis
ATE271384T1 (de) Arylnitron therapeutische mittel zur behandlung von entzündlichen darmerkrankungen
SE9901273D0 (sv) Novel compounds
MXPA01009174A (es) Antagonistas de endotelina novedosos derivados de piridazina.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties